Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)

• Register: ChiCTR
• Last refreshed on: 16 March 2020
• Main ID: ChiCTR2000030329
• Date of registration: 2020-02-28
• Prospective Registration: Yes
• Primary sponsor: The Second Affiliated Hospital of Xi'an Medical University
• Public title: Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)
• Scientific title: Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)
• Date of first enrolment: 2020-03-05
• Target sample size: Control group:30;CIK group:30;NK group:30;
• Recruitment status: Pending
• URL: http://www.chictr.org.cn/showproj.aspx?proj=49779
• Study type: Interventional study
• Study design: Parallel
• Phase: 0

Countries of recruitment

China

Contacts

• Name: Gao Jun
• Affiliation: The Second Affiliated Hospital of Xi'an Medical University

• Name: Gao Jun
• Affiliation: The Second Affiliated Hospital of Xi'an Medical University

Key inclusion & exclusion criteria

Inclusion criteria: 1. New-type coronavirus infection is diagnosed as mild or common (diagnosed according to the "Notice on the Issuance of a New Coronavirus-Infected Pneumonia Diagnosis and Treatment Plan (Trial Implementation of the Sixth Edition)") or patients with poor immune function (cured discharged patients but peripheral hemolymph Cell count and classification are abnormal).
2. Aged 18-65 years;
3. Sign informed consent.
Exclusion criteria: Doctors and researchers consider that the patient inappropriate to enroll in the study.

Age minimum: 18
Age maximum: 65
Gender: Both

Health Condition(s) or Problem(s) studied

Novel Coronavirus Pneumonia (COVID-19)

Intervention(s)

Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.6×10E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.6×10E8/kg) were injected twice every other day.;

Primary Outcome(s)

Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;

Secondary Outcome(s)

The incidence rate of complication;

Source(s) of Monetary Support

Xi'an Medical university

Ethics review

Status: Approved
Approval date: 14/02/2020
Contact:

[e-mail]

Dan Wang

[phone]

[e-mail]